Kerner Hilit, Samuels Noah, Ben Moshe Shlomi, Sharabi Ilanit Shalom, Ben-Arye Eran
Integrative Oncology Program, The Oncology Service and Lin Medical Center, Clalit Health Services, Haifa, Israel.
Family Medicine Department, Technion-Israel Institute of Technology, Haifa, Israel.
BMJ Support Palliat Care. 2020 Sep;10(3):e21. doi: 10.1136/bmjspcare-2017-001351. Epub 2017 Jul 14.
The present study examined the impact of a patient-tailored complementary/integrative medicine (CIM) programme on sleep quality in patients undergoing chemotherapy for breast and gynaecological cancer.
Study participants received standard supportive care, with or without weekly CIM treatments. Disturbed sleep quality was defined as a score of ≥4 on the Edmonton Symptom Assessment Scale (ESAS) or a score of ≥3 on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Adherence to integrative care was defined as attending ≥4 CIM treatments, with ≤30 days between each session.
Of 388 eligible patients, 264 (68%) reported disturbed sleep quality. Baseline-to-follow up assessment (at 6 weeks) was optimal for 104 patients in the treatment group and for 76 controls, with 75 of treated patients found to be adherent to the CIM intervention. Sleep-related ESAS scores improved more significantly in treated patients (p=0.008), as did sleep-related concerns on EORTC (treatment group, p=0.026).
A patient-tailored CIM programme may improve sleep quality and related concerns among patients with breast and gynaecological cancer undergoing chemotherapy. Further research is needed to better understand the impact of CIM on sleep quality in this patient population.
NCT01860365.
本研究探讨了针对患者量身定制的补充/整合医学（CIM）方案对乳腺癌和妇科癌症化疗患者睡眠质量的影响。
研究参与者接受标准支持性护理，部分接受每周一次的CIM治疗。睡眠质量受干扰被定义为埃德蒙顿症状评估量表（ESAS）得分≥4分，或欧洲癌症研究与治疗组织生活质量问卷（EORTC QLQ-C30）得分≥3分。综合护理的依从性定义为参加≥4次CIM治疗，且每次治疗间隔≤30天。
在388名符合条件的患者中，264名（68%）报告睡眠质量受干扰。治疗组104名患者和76名对照组患者在基线至随访评估（6周时）情况最佳，其中75名接受治疗的患者坚持接受了CIM干预。接受治疗的患者中，与睡眠相关的ESAS评分改善更为显著（p = 0.008），欧洲癌症研究与治疗组织问卷中与睡眠相关的问题也是如此（治疗组，p = 0.026）。
针对患者量身定制的CIM方案可能改善乳腺癌和妇科癌症化疗患者的睡眠质量及相关问题。需要进一步研究以更好地了解CIM对该患者群体睡眠质量的影响。
NCT01860365。
